Researchers compared a potent antiplatelet inhibition strategy with a less potent inhibition treatment plan in patients with acute coronary syndrome undergoing coronary artery bypass surgery.
The risk for 10-year all-cause mortality was found to be comparable after PCI and CABG in patients with prior cerebrovascular disease.
Addition of evolocumab to statin therapy was found to lower the risk for complex coronary disease requiring revascularization.
Use of radial artery vs saphenous vein for coronary artery bypass grafting was found to be associated with a reduced long-term risk for a composite of cardiovascular outcomes.
The estimation of myocardial flow reserve using positron emission tomography may help identify patients with ischemic heart failure who would have improved outcomes with early coronary artery bypass grafting vs percutaneous coronary intervention.
Patients with vs without peripheral artery disease may be at higher risk for stroke, acute kidney disease, and limb ischemia after coronary artery bypass grafting surgery.
Several risk factors for new persistent opioid use after coronary artery bypass grafting were identified.
The use of percutaneous coronary intervention and coronary artery bypass grafting for the treatment of left main coronary artery disease of low or intermediate anatomic complexity was found to be associated with comparable rates of a composite of death, stroke, and myocardial infarction at 5 years.
Findings reinforce need for a team approach to treatment decisions for heart conditions.
No significant difference seen for patients undergoing CABG with volatile anesthesia.
